journal article·2026-02-10Open access

Innovative Skin Depigmenting Strategies: A Review

Rita Carneiro, Carla M. Lopes, Maria Helena Amaral

Applied Sciences· Volume 16· Issue 4

Abstract

Skin pigmentation results from the melanin production by melanocytes, an essential process for protection against ultraviolet radiation and for maintaining cutaneous homeostasis. Disruptions in this balance lead to pigmentary disorders, such as hyperpigmentation, which is characterized by localized or diffuse darkening of the skin. Its most prevalent forms include melasma, post-inflammatory hyperpigmentation, and solar lentigines, often driven by hormonal, inflammatory, and environmental factors, particularly sun exposure. Despite being clinically benign, these conditions have a significant impact on self-esteem and quality of life. Conventional treatments rely on depigmenting agents such as hydroquinone, retinoids, and corticosteroids, as well as chemical peels, and laser or light-based therapies, frequently used in combination. However, limited efficacy, prolonged treatment durations, and potential adverse effects underscore the need for safer and more effective alternatives. In recent years, research has focused on developing novel approaches, with nanotechnology-based delivery systems and minimally invasive techniques, such as microneedling, standing out as particularly promising fields. In parallel, the growing number of interventional clinical trials reflects an increasing interest in optimizing topical depigmenting strategies. This review summarizes the main types of hyperpigmentation, the depigmenting substances currently used, and emerging therapeutic approaches with potential clinical impact.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Dermatologic Treatments and Research · melanin and skin pigmentation · Laser Applications in Dentistry and Medicine

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

UCIBIO—Applied Molecular Biosciences Unit, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

Associate Laboratory i4HB, Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

FP-BHS—Biomedical and Health Sciences Research Unit, FFP-I3ID—Instituto de Investigação, Inovação e Desenvolvimento, Faculdade Ciências da Saúde, Universidade Fernando Pessoa, Rua Carlos da Maia 296, 4200-150 Porto, Portugal

RISE—Health Research Network: From the Lab to the Community, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal

Funding

FCT—Fundação para a Ciência e a Tecnologia, I.P. · Research Unit on Applied Molecular Biosciences—UCIBIO · Associate Laboratory Institute for Health and Bioeconomy—i4HB

References (68)

Show source-provided references
1. Jin, R., Luo, L., and Zheng, J. (2022). The Trinity of skin: Skin homeostasis as a neuro-endocrine-immune organ. Life, 12.10.3390/life12050725 ↗
2. Nguyen, A.V., and Soulika, A.M. (2019). The dynamics of the skin’s immune system. Int. J. Mol. Sci., 20.10.3390/ijms20081811 ↗
3. Li, C., Kuai, L., Cui, R., and Miao, X. (2022). Melanogenesis and the targeted therapy of melanoma. Biomolecules, 12.10.3390/biom12121874 ↗
4. Thawabteh, A.M., Jibreen, A., Karaman, D., Thawabteh, A., and Karaman, R. (2023). Skin pigmentation types, causes and treatment—A review. Molecules, 28.10.20944/preprints202305.0751.v1 ↗
5. Skin type diversity in skin lesion datasets: A review10.1007/s13671-024-00440-0 ↗
6. Management of hyperpigmentation: Current treatments and emerging therapies10.1111/pcmr.12986 ↗
7. Disorders of pigmentation10.1111/j.1610-0387.2009.07137.x ↗
8. Advancements in drug delivery for hyperpigmentation: Emerging therapies and future prospects10.1080/15569527.2025.2524683 ↗
9. Hyperpigmentation therapy: A review
10. Pigmentary disorders, prevalence, impact on quality of life and social stigmatization: Results of the first large international survey10.1016/j.jaad.2024.07.1114 ↗
11. Prevalence of pigmentary disorders and their impact on quality of life: A prospective cohort study10.1111/j.1473-2165.2008.00384.x ↗
12. The impact of hyperpigmentation on the lives of patients10.36849/JDD.8519 ↗
13. Skin lightening preparations and the hydroquinone controversy: Hydroquinone and skin lightening preparations10.1111/j.1529-8019.2007.00144.x ↗
14. Ghasemiyeh, P., Fazlinejad, R., Kiafar, M.R., Rasekh, S., Mokhtarzadegan, M., and Mohammadi-Samani, S. (2024). Different therapeutic approaches in melasma: Advances and limitations. Front. Pharmacol., 15.10.3389/fphar.2024.1337282 ↗
15. Mechanisms of ultraviolet light-induced pigmentation10.1111/j.1751-1097.1996.tb02988.x ↗
16. The potential role of antioxidants in mitigating skin hyperpigmentation resulting from ultraviolet and visible light-induced oxidative stress10.1111/phpp.12423 ↗
17. Melasma: An up-to-date comprehensive review10.1007/s13555-017-0194-1 ↗
18. Differential diagnosis of melasma and hyperpigmentation10.1002/der2.144 ↗
19. Qu, Y., Wang, S., Xie, H., Meng, X., Cui, B., and Xiao, Z. (2025). Melasma secondary to drugs: A real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS). BMC Pharmacol. Toxicol., 26.10.1186/s40360-025-00912-4 ↗
20. A focused review on the pathophysiology of post-inflammatory hyperpigmentation10.1111/pcmr.13038 ↗
21. Overview on post-inflammatory hyperpigmentation10.9734/jpri/2021/v33i63A35864 ↗
22. Postinflammatory hyperpigmentation: Review of pathogenesis, prevention, and treatment10.4103/2349-5847.147043 ↗
23. Lawrence, E., Syed, H.A., and Al Aboud, K.M. (2025, November 15). Postinflammatory hyperpigmentation, StatPearls, Available online: https://www.ncbi.nlm.nih.gov/books/NBK559150/.
24. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment10.2165/00128071-200102040-00006 ↗
26. Drug-induced pigmentation: A review10.1007/s40265-024-02062-z ↗
27. Drug-induced hyperpigmentation: Review and case series10.3122/jabfm.2019.04.180212 ↗
28. Camayo, T.V., Lee, V.R., and Zhou, X.A. (2025, November 16). Drug-induced pigmentation, StatPearls, Available online: https://www.ncbi.nlm.nih.gov/books/NBK542253/.
29. Arni, C., and Preclaro, I. (2023). Drug-induced pigmentation. Pigmentation Disorders—Etiology and Recent Advances in Treatments, IntechOpen.10.5772/intechopen.108680 ↗
30. Novel preventive and therapeutic strategies for ephelides (freckles) from a Persian medicine perspective: A narrative review10.5812/jssc-123335 ↗
31. Pigmentation disorders: Diagnosis and management
32. Couteau, C., and Coiffard, L. (2016). Overview of skin whitening agents: Drugs and cosmetic products. Cosmetics, 3.10.3390/cosmetics3030027 ↗
33. Skin lightening & management of hyperpigmentation
34. Topical hydroquinone for hyperpigmentation: A narrative review
35. Burger, P., Landreau, A., Azoulay, S., Michel, T., and Fernandez, X. (2016). Skin whitening cosmetics: Feedback and challenges in the development of natural skin lighteners. Cosmetics, 3.10.3390/cosmetics3040036 ↗
36. Review on analysis of interesting whitening agents in cosmetics products10.1088/1757-899X/928/5/052001 ↗
37. Phasha, V., Senabe, J., Ndzotoyi, P., Okole, B., Fouche, G., and Chuturgoon, A. (2022). Review on the use of Kojic Acid—A skin-lightening ingredient. Cosmetics, 9.10.3390/cosmetics9030064 ↗
38. Petrovici, A.-G., Spennato, M., Bîtcan, I., Péter, F., Cotarcă, L., Todea, A., and Ordodi, V.L. (2025). A comprehensive review of azelaic acid pharmacological properties, clinical applications, and innovative topical formulations. Pharmaceuticals, 18.10.3390/ph18091273 ↗
39. Comparative study on depigmenting agents in skin of color
40. Postinflammatory hyperpigmentation: A review of the epidemiology, clinical features, and treatment options in skin of color
41. Chambers, C. (2008). Opinion on Kojic Acid, Scientific Committee on Consumer Products.
43. The melanogenesis and mechanisms of skin-lightening agents-existing and new approaches: Melanogenesis and skin-lightening agents10.1111/j.1468-2494.2010.00616.x ↗
44. Current clinical use of depigmenting agents10.1016/j.dsi.2014.07.003 ↗
45. Mechanisms regulating skin pigmentation: The rise and fall of complexion coloration10.3390/ijms10094066 ↗
46. Fan, M., Fan, X., Lai, Y., Chen, J., Peng, Y., Peng, Y., Xiang, L., and Ma, Y. (2024). Protease-Activated Receptor 2 in inflammatory skin disease: Current evidence and future perspectives. Front. Immunol., 15.10.3389/fimmu.2024.1448952 ↗
47. Effects of methylophiopogonanone B on melanosome transfer and dendrite retraction10.1016/j.jdermsci.2005.12.015 ↗
48. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer10.1046/j.1365-2133.2002.04834.x ↗
49. Hypopigmenting agents: An updated review on biological, chemical and clinical aspects10.1111/j.1600-0749.2006.00334.x ↗
50. Inhibition of melanosome transfer from melanocytes to keratinocytes by lectins and neoglycoproteins in an in vitro model system10.1034/j.1600-0749.2001.140308.x ↗
51. The antityrosinase and antioxidant activities of flavonoids dominated by the number and location of phenolic hydroxyl groups10.1186/s13020-018-0206-9 ↗
52. Augmented glutathione absorption from oral mucosa and its effect on skin pigmentation: A clinical review10.2147/CCID.S378470 ↗
53. A review of oral therapies for the treatment of skin hyperpigmentation10.1177/12034754211045391 ↗
54. An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women10.1111/ijd.12999 ↗
55. Peng, X., Ma, Y., Yan, C., Wei, X., Zhang, L., Jiang, H., Ma, Y., Zhang, S., Xing, M., and Gao, Y. (2024). Mechanism, formulation, and efficacy evaluation of natural products for skin pigmentation treatment. Pharmaceutics, 16.10.3390/pharmaceutics16081022 ↗
56. Singh, S., Sharma, N., Zahoor, I., Behl, T., Antil, A., Gupta, S., Anwer, M.K., Mohan, S., and Bungau, S.G. (2022). Decrypting the potential of nanotechnology-based approaches as cutting-edge for management of hyperpigmentation disorder. Molecules, 28.10.3390/molecules28010220 ↗
57. Advances in cosmeceutical nanotechnology for hyperpigmentation treatment10.1007/s11051-022-05534-z ↗
58. Liposomes for drug delivery: Classification, therapeutic applications, and limitations10.1016/j.nxnano.2025.100209 ↗
59. Roselan, M.A., Ashari, S.E., Faujan, N.H., Mohd Faudzi, S.M., and Mohamad, R. (2020). An improved nanoemulsion formulation containing kojic monooleate: Optimization, characterization and in vitro studies. Molecules, 25.10.3390/molecules25112616 ↗
60. Nanoparticle-in-gel system for delivery of vitamin C for topical application10.1007/s13346-017-0398-z ↗
61. Madawi, E.A., Al Jayoush, A.R., Rawas-Qalaji, M., Thu, H.E., Khan, S., Sohail, M., Mahmood, A., and Hussain, Z. (2023). Polymeric nanoparticles as tunable nanocarriers for targeted delivery of drugs to skin tissues for treatment of topical skin diseases. Pharmaceutics, 15.10.3390/pharmaceutics15020657 ↗
62. Inhibitory effect of the water-soluble polymer-wrapped derivative of fullerene on UVA-induced melanogenesis via downregulation of tyrosinase expression in human melanocytes and skin tissues10.1007/s00403-007-0740-2 ↗
63. Efficiency of ellagic acid and arbutin in melasma: A randomized, prospective, open-label study10.1111/j.1346-8138.2008.00522.x ↗
64. Interaction of inorganic nanoparticles with the skin barrier: Current status and critical review10.1016/j.nano.2012.04.004 ↗
65. Microneedling-assisted delivery of metformin versus tranexamic acid in treating melasma: A randomized controlled study10.1186/s40001-025-03032-1 ↗
66. Evaluation of the effectiveness of microneedling with tranexamic acid in comparison with microneedling with vitamin C in the treatment of melasma: A prospective and single-blind clinical trial10.1002/hsr2.1636 ↗
67. Systematic review of randomized controlled trials on interventions for melasma: An abridged Cochrane review10.1016/j.jaad.2013.07.044 ↗
68. Wang, T., Wang, Y., Wang, J., Chen, H., Qu, B., and Li, Z. (2021). Efficacy and safety of topical therapy with botanical products for Melasma: A systematic review and meta-analysis of randomized controlled trials. Front. Med., 8.10.3389/fmed.2021.797890 ↗